No Data
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Latest research confirms: Novo-Nordisk A/S Ozempic is associated with a rare risk of vision loss.
① A latest study confirms that Ozempic, a star drug from the Danish pharmaceutical giant Novo-Nordisk A/S, is associated with an increased risk of a rare eye disease that leads to vision loss; ② According to an analysis by Nordic researchers of years of patient records from Denmark and Norway, diabetic patients using Ozempic are more than twice as likely to develop NAION compared to patients using another diabetes medication.
Market Whales and Their Recent Bets on NVO Options
Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
'Ozempic Link to Rare Vision Loss Risk Confirmed in Study; Risk of Eye Condition Remains Low; Patients Should Be Aware; NAION Occurs When Loss of Blood Flow Damages Optic Nerve' - Bloomberg News
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
